Ribociclib for the adjuvant treatment of HR-positive, HER2-negative stage II and III early breast cancer at high risk of recurrence
Agency for Care Effectiveness (ACE)
Record ID 32018015218
English
Details
Project Status:
Completed
Year Published:
2026
URL for published report:
https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidances/drug-guidance/ribociclib-for-the-adjuvant-treatment-of-hr-positive--her2-negative-stage-ii-and-iii-early-breast-cancer-at-high-risk-of-recurrence/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Singapore
MeSH Terms
- Breast Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- Aminopyridines
- Purines
Contact
Organisation Name:
Agency for Care Effectiveness (ACE)
Contact Address:
Ministry of Health, College of Medicine Building, 16 College Road, Singapore 169854
Contact Name:
ACE_HTA@moh.gov.sg
Contact Email:
ACE_HTA@moh.gov.sg
Copyright:
Agency for Care Effectiveness (ACE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.